EUCTR2016-003729-41-IT进行中（未招募）1 期
A Phase 3, Randomized Study of Adjuvant Immunotherapy with NivolumabCombined with Ipilimumab Versus Nivolumab Monotherapy after CompleteResection of Stage IIIb/c/d or Stage IV Melanoma. - CheckMate 915
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 1,844
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Completely surgically resected stage IIIb/c/d or stage IV melanoma
- •within 12 weeks of participation in study;
- •- Must have full activity or, if limited, must be able to walk and carry out
- •activities such as light house work or office work;
- •- No prior anti-cancer treatment for melanoma (except surgery for the
- •melanoma lesion(s) and/or except for adjuvant radiation therapy (RT)
- •after neurosurgical resection for central nervous system (CNS) lesions).
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 2426
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 857
排除标准
- •_History of ocular/uveal melanoma;
- •_Patients with active, known or suspected autoimmune disease;
- •_Prior treatment with interferon (if complete < 6 months prior to
- •participation in study), anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or
- •anti-CTLA-4 antibody, or any other antibody or drug specifically
- •targeting T-cell co-stimulation or checkpoint pathways.
研究者
相似试验
进行中（未招募）
1 期
A Study of Nivolumab in Combination with Ipilimumab Compared to Nivolumab or Ipilimumab Alone in Treatment of Patients After Complete Resection of Stage IIIb/c/d or Stage IV Melanoma.Stage IIIb/c/d or Stage IV no evidence of disease (NED) melanoma following complete resection of the lesion(s) with high risk of relapse.MedDRA version: 19.1Level: LLTClassification code 10053571Term: MelanomaSystem Organ Class: 100000004864MedDRA version: 19.1Level: LLTClassification code 10040891Term: Skin melanomaSystem Organ Class: 100000004864EUCTR2016-003729-41-ESBristol-Myers Squibb International Corporation1,125
进行中（未招募）
1 期
A Study of Nivolumab in Combination with Ipilimumab Compared to Nivolumab Alone in Treatment of Patients After Complete Resection of Stage IIIb/c/d or Stage IV Melanoma.EUCTR2016-003729-41-GBBristol-Myers Squibb International Corporation2,560
进行中（未招募）
1 期
A Study of Nivolumab in Combination with Ipilimumab Compared to Nivolumab Alone in Treatment of Patients After Complete Resection of Stage IIIb/c/d or Stage IV Melanoma.Stage IIIb/c/d or Stage IV no evidence of disease (NED) melanoma following complete resection of the lesion(s) with high risk of relapse.MedDRA version: 20.0Level: LLTClassification code 10053571Term: MelanomaSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10040891Term: Skin melanomaSystem Organ Class: 100000004864EUCTR2016-003729-41-BEBristol-Myers Squibb International Corporation2,560
进行中（未招募）
1 期
A Study of Nivolumab in Combination with Ipilimumab Compared to Nivolumab Alone in Treatment of Patients After Complete Resection of Stage IIIb/c/d or Stage IV Melanoma.EUCTR2016-003729-41-Outside-EU/EEABristol-Myers Squibb International Corporation1,844
进行中（未招募）
1 期
A Study of Nivolumab in Combination with Ipilimumab Compared to Nivolumab Alone in Treatment of Patients After Complete Resection of Stage IIIb/c/d or Stage IV Melanoma.EUCTR2016-003729-41-PLBristol-Myers Squibb International Corporation1,844